The Incidence of Ototoxicity in Patients Using Iron Chelators
Muğla Sıtkı Koçman University School of Medicine, Department of Otolaryngology, Muğla, Turkey
Muğla Sıtkı Koçman University School of Medicine, Department of Pediatric Hematology and Oncology, Muğla, Turkey
Muğla Sıtkı Koçman University School of Medicine, Department of Pediatrics, Muğla, Turkey
Muğla Sıtkı Koçman University School of Medicine, Department of Internal Medicine, Muğla, Turkey
Muğla Yücelen Hospital, Department of Pediatrics, Muğla, Turkey
J Int Adv Otol ; : -
This article was viewed 323 times, downloaded 148 times
Key Words: Deferoxamine, deferiprone, deferasirox, hemoglobinopathies, ototoxicity
OBJECTIVE: In this study, we aimed to detect the incidences of ototoxicity in patients with hemoglobinopathies taking deferoxamine (DFO), deferiprone, and deferasirox using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) scale to obtain more objective data.
MATERIALS and METHODS: Fifty-five transfusion-dependent patients were evaluated in this study. The NCI CTCAE scale was used to assess ototoxicity levels. The average ferritin and hemoglobin levels, the type of iron chelator, and the duration of therapy of all the patients were recorded.
RESULTS: Ototoxicity was observed in 15 patients (31.9 %), all of whom were taking DFO. The median age was 19.5 (6–43) in patients without ototoxicity and 29 (16–50) in those with ototoxicity; this difference was statistically significant (p<0.05). The median ferritin and pre-tx Hb levels were 1391 ng/mL and 9.06 mg/dL, respectively, in patients with ototoxicity and 986.7 ng/mL and 9.24 mg/dL, respectively, in those without ototoxicity; these differences were not significant (p>0.05). Ototoxicity was not observed in the eight patients who used only deferasirox and deferiprone.
CONCLUSION: The ototoxicity incidence with DFO at doses below 50 mg/kg/day was 27.3%. Deferiprone and deferasirox were not associated with ototoxic effects in patients taking these drugs.